Protea Vaccine Technologies Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Protea Vaccine Technologies General Information

Description

Developer of a proprietary identification and prioritization platform designed for the discovery of conserved protein antigens. The company specializes in the development and commercialization of pneumonia vaccines to protect against pneumococcal serotypes and pneumonia prevalent among humans of all ages in all geographical locations.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Meytav Technological Incubator
  • P.O.Box 408
  • Kiryat Shmona 11013
  • Israel
+972
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Drug Discovery
Acquirer
Eledon Pharmaceuticals
Vertical(s)
SaaS, Life Sciences
Corporate Office
  • Meytav Technological Incubator
  • P.O.Box 408
  • Kiryat Shmona 11013
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Protea Vaccine Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Protea Vaccine Technologies‘s full profile, request access.

Request a free trial

Protea Vaccine Technologies Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Protea Vaccine Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2011128892-A2 Modified forms of pneumococcal surface immunogenic protein b (psipb) Inactive 12-Apr-2010
WO-2011128892-A3 Modified forms of pneumococcal surface immunogenic protein b (psipb) Inactive 12-Apr-2010
WO-2011067758-A2 Immunogenic fragments and multimers from streptococcus pneumoniae proteins Inactive 02-Dec-2009
WO-2011067758-A3 Immunogenic fragments and multimers from streptococcus pneumoniae proteins Inactive 02-Dec-2009
WO-2010150242-A2 Immunogenic streptococcus pneumoniae peptides and peptide-multimers Inactive 25-Jun-2009 C07K14/3156
To view Protea Vaccine Technologies’s complete patent history, request access »

Protea Vaccine Technologies FAQs

  • When was Protea Vaccine Technologies founded?

    Protea Vaccine Technologies was founded in 2006.

  • Where is Protea Vaccine Technologies headquartered?

    Protea Vaccine Technologies is headquartered in Kiryat Shmona, Israel.

  • What industry is Protea Vaccine Technologies in?

    Protea Vaccine Technologies’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Protea Vaccine Technologies a private or public company?

    Protea Vaccine Technologies is a Private company.

  • What is Protea Vaccine Technologies’s current revenue?

    The current revenue for Protea Vaccine Technologies is .

  • When was Protea Vaccine Technologies acquired?

    Protea Vaccine Technologies was acquired on 01-Dec-2008.

  • Who acquired Protea Vaccine Technologies?

    Protea Vaccine Technologies was acquired by Eledon Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process